2012 Annual Report Maureen O’Grady Finds a New Reason to Hope Bristol-Myers Squibb  15 r “By focusing so many resources on  immuno-oncology, we are going to  fundamentally change the way we  think about cancer,” he says. “We do  not have time to waste. Every day is  important for cancer patients.” Bristol-Myers Squibb is also working  with payers and other key stakehold- ers to understand how to assess the  Bristol-Myers Squibb. This network  allows us to leverage the best science  from around the world while also more  efficiently conducting clinical experi- ments. The network will help us make  some important strategic decisions  and allows us to move science along  much faster.” value of these new medicines. “Tra- ditional standards of median survival  do not fully capture the value of the  long-term survival benefits being seen  in patients,” LaCaze adds. mid-2012, we formed the International  Immuno-Oncology Network, an inno- vative academic research collabora- tion with 10 leading cancer research  centers around the world.  “The science of immuno-oncology  is evolving very rapidly, and to stay  at the forefront, we streamlined the  process of engaging academic lead- ers,” Lonberg says. “After all, we don’t  have a monopoly on science within  “While I’ve been on treatment, I’ve experienced so many  milestones – from college graduations and weddings, to the  birth of my grandsons, my own 40th high school reunion  and my 39th anniversary with my husband,” O’Grady says.  “I couldn’t be here today without the outpouring of love and  care from my family and friends, my faith and the treatments  I have received. I think it’s the trifecta of my success.” In June 2010, O’Grady was offered a new option, to enter  a clinical trial for a different type of therapy – an investi- gational immunotherapy called nivolumab (BMS-936558,  anti-PD-1), a compound from Bristol-Myers Squibb still  in development. “It caught my eye because it was actu - ally going to improve my immune system to recognize the  cancer and train my cells to attack it,” she says. Today, her  doctors are optimistic: the tumors have all shrunk, and the  cancer has stopped spreading.  Then, a second oncologist, this time at the Smilow Cancer  Hospital at yale university in New Haven, gave her a ray of  hope. She recalls: “He said, ‘you’re not curable, but you are  treatable.’” First came an aggressive chemotherapy regi - men, then a second oral drug and after that, an investiga- tional compound. Her cancer continued to spread. Concerned about a cough that wouldn’t go away, in Janu - ary 2009, O’Grady had an x-ray and follow-up tests that  confirmed a devastating diagnosis: stage IV lung cancer,  including a large mass in her right lung, and cancer lesions  on her liver and kidney. Her first oncologist thought she  might live another 12-18 months. “I had no hope,” she later  said. “I was given an expiration date.” “Before my diagnosis, we were having a great time,” says  Maureen O’Grady, of Milford, Connecticut. “Then I got the  worst news of my life.” Maureen O’Grady